ClinicalTrials.gg

Diabetic Foot clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,079 studies for Diabetic Foot across more than 10 countries. 222 are recruiting or about to start. 944 of them are mainly about Diabetic Foot (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 1,281 studies for Diabetic Foot. How that becomes 1,077 here

This page counts the studies the registry files under Diabetic Foot, and those it files under no condition that list Diabetic Footthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,281Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −30List Diabetic Foot as a condition, but the registry did not file them under itMost often written as “Diabetic Foot Disease” (5), “Foot Ulcers, Diabetic” (4), and “Diabetic Foot Infection” (4). The registry filed them under other conditions only, most often Foot Ulcer (7) and Diabetes Mellitus (6).
  3. −174Match it another way82 name it in the title, 3 in a keyword, and 89 by a synonym or other text the search reads.
  4. 1,077The count on this page45 of them list Diabetic Foot in their own words; the registry filed them under no condition.

Status

Completed
532
Status unknown
146
Recruiting
138
Terminated
95
Not yet recruiting
72
Active, not recruiting
45

Phase

Phase 2
140
Phase 1
88
Phase 3
84
Phase 4
57
Early Phase 1
12

Where

United States
381
United Kingdom
60
France
55
China
52
Turkey
47
Spain
40

Who develops what

Add Diabetic Foot to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 7 with this as their studies’ main aim; 2 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
LinezolidRecent, limited
Evidence
  • NCT05369052 · MicuRx · Phase 3 · live · comparator · “Linezolid (IV and PO)” · registered Apr 2022
Pfizer78% of its industry studiesUS: off-patent, 16 generics marketed11 study
LevofloxacinEarlier only
Evidence
  • NCT00593567 · Innocoll · Phase 2 · comparator · “Levofloxacin” · registered Jan 2008
  • NCT00516958 · Oculus Innovative Sciences, Inc. · Phase 2 · comparator · “Topical Dermacyn and Levofloxacin” · registered Aug 2007
Johnson & Johnson55% of its industry studiesEU: Chiesi Farmaceutici S.p.A. (EMA 2015)00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
BIOxHEAL (human amniotic membrane allograft)☆ Track1 live phase-3 study: NCT07852338Applied Biologics, LLC
Amniotic Tissue Allograft☆ Track1 live phase-3 study: NCT07223892Bardia Anvar

The 2 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Sep 2027 est.BIOxHEAL (human amniotic membrane allograft) · Applied Biologics, LLC · Phase 3 main aimNCT07852338 a Prospective, Multicenter, Randomized Controlled Trial, With a Non-randomized Sentinel Cohort, Evaluating the Efficacy of Bioxheal, a Single-layer Placental-derived Biologic in Nonhealing Diabetic Foot Ulcers — primary endpoint: Proportion of target ulcers with complete wound closure at Week 12 · 253 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Diabetic Foot studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

84studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 138 Diabetic Foot studies recruiting now, 97 (70%) set no upper age limit and 12 (9%) stop at 75 or younger. 5 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 10 (7%) take healthy volunteers.

Recruiting studies that take each age, of 138
AgeWomenMen
105 (4%)5 (4%)
18116 (84%)116 (84%)
30134 (97%)134 (97%)
40135 (98%)135 (98%)
50137 (99%)137 (99%)
65137 (99%)137 (99%)
75136 (99%)136 (99%)
85112 (81%)112 (81%)

Across all 1,079 studies, recruiting or not: 13% stop at 75 or younger and 5% at 65; 4% take children; 0% are for women only and <1% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Diabetic Foot studies take

Of 31 phase 2 interventional studies under Diabetic Foot, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 129 mo13–43 · 26 studies——
Phase 1/226 mo18–37 · 18 studies——
Phase 233 mo19–47 · 31 studies——
Phase 342 mo23–64 · 18 studies——
Phase 417 mo11–50 · 21 studies——
Interventional, no phase22 mo9–39 · 345 studies25 mo12–40 · 104 studies21 mo7–37 · 241 studies
Observational29 mo15–59 · 90 studies—29 mo12–94 · 65 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,079. Browse all 1,079 → or search them.